The background is reports that AstraZeneca has made a bid of around USD 10 billion for US-based Rhythm Pharmaceuticals. According to EFN’s Jonathan Axelsson the acquisition interest also raises the question of the future of Investor-controlled Sobi, in which AstraZeneca owns just under 10 percent of the votes.
In 2021, AstraZeneca blocked a takeover bid for Sobi from the private equity firms Advent and GIC, despite the fact that major shareholder Investor had accepted the offer. The bid was SEK 235 per share, while Sobi currently trades at around SEK 485 and is valued at approximately SEK 170 billion.
EFN: Could AstraZeneca make a move for Sobi?
Pharmaceutical company Sobi could face either a takeover by AstraZeneca or continued expansion on its own when Börje Ekholm takes over as chairman next spring. EFN’s Jonathan Axelsson wrote in a commentary.
Advertisement
BREAKING